Recent

% | $
Quotes you view appear here for quick access.

China Commercial Credit, Inc. Message Board

garysnoop1 300 posts  |  Last Activity: 20 hours ago Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • garysnoop1 by garysnoop1 Jun 22, 2016 9:31 AM Flag

    Inovio Pharmaceuticals Equity Analysis

    Inovio Pharmaceuticals Inc. (NASDAQ:INO) opened trading today as $11.26 and is trading in the range of 11.25-11.61 today. Inovio Pharmaceuticals’ current market cap stands at $823.07 million.

    Compared to other peers in the Biotechnology sector, Inovio Pharmaceuticals has outperformed in terms of quarterly revenue growth year over year at .57 vs. the industry average of 0.19. Inovio Pharmaceuticals’ earnings per share is currently at -0.38 which is higher than the sector average of -0.39.

    Inovio Pharmaceuticals is currently covered by 5 Wall Street analysts. The mean target price is $15.50 according to First Call. This presents a solid upside to the current price of the equity. The Mean Recommendation sits at 1.6 which is based on, 2 Strong buy and 3 Buy.

    The most recent analyst actions consisted of H.C. Wainwright initiating the stock on March 12th and Aegis Capital initiating coverage with an upgrading rating back in July.

    The current quarter EPS consensus estimate is -0.21 with revenue estimates of 4.96M. Sales are expected to drop at a 6.20% rate. Inovio Pharmaceuticals reported actual earnings last quarter of -0.11 which beat the -0.14 consensus estimate, a 21.40% surprise.

    Corporate Profile

    Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

  • Reply to

    Expect Big Days Ahead

    by patcarr832 Jun 20, 2016 5:28 PM
    garysnoop1 garysnoop1 Jun 20, 2016 5:34 PM Flag

    More likely than not Pat.

    Sentiment: Strong Buy

  • Reply to

    Inovio and Gene one start Zika testing.

    by garysnoop1 Jun 20, 2016 8:41 AM
    garysnoop1 garysnoop1 Jun 20, 2016 4:11 PM Flag

    This is what will push this stock up..Not the animal rule as stated..

    Sentiment: Strong Buy

  • will takeoff tomorrow..

    Sentiment: Strong Buy

  • garysnoop1 garysnoop1 Jun 20, 2016 3:31 PM Flag

    55 gal. jug!!

  • garysnoop1 garysnoop1 Jun 20, 2016 1:40 PM Flag

    Just left their job at GM as test dummies..

  • garysnoop1 garysnoop1 Jun 20, 2016 12:28 PM Flag

    I see you have a new nane for the same old AH..

  • Inovio Pharmaceuticals Inc (NASDAQ:INO) is up 3.7% at $10.86, after the drugmaker -- and its partner GeneOne Life Sciences Inc -- was given the go-ahead by U.S. regulators to begin human testing of its Zika vaccine. This echoes well-received news for sector peer Hologic, Inc. (NASDAQ:HOLX), and, according to INO CEO Dr. Joseph Kim, the early stage testing will begin in the next few weeks. Meanwhile, traders are once again showing a preference for calls over puts in INO stock's lightly traded options pits, with 2347 of the former and just 44 of the latter on the tape at last check.

    Looking back over the past 50 trading sessions reveals more of the same in INO's options pits. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), for instance, options traders have bought to open 6,078 call options compared to 324 put options, resulting in a top-heavy call/put volume ratio of 18.76.

    Elsewhere, INO sports a Schaeffer's put/call open interest ratio (SOIR) of 0.19. Not only does this show that calls outweigh puts by a more than 5-to-1 margin among options expiring in three months or less, but it ranks lower than 87% of all comparable readings taken in the past year. Simply stated, short-term speculators are more call-heavy than usual toward INO.

    With 16.3% of the stock's float sold short, though, there could be an ulterior motive for this recent batch of call buying. Specifically, it could be that short sellers are initiating protective calls to hedge against any upside risk.

    Regardless of the reason, now is an opportune time to purchase premium on INO's short-term options. The equity's Schaeffer's Volatility Index (SVI) of 58% rests in just the 16th percentile of its annual range, meaning the options market is pricing in relatively low volatility expectations at the moment.

  • Key word....FIRST !! For the shorts,that means they are ahead of every one else..digest that..SSB..

    Sentiment: Strong Buy

  • Reply to

    Inovio and Gene one start Zika testing.

    by garysnoop1 Jun 20, 2016 8:41 AM
    garysnoop1 garysnoop1 Jun 20, 2016 9:05 AM Flag

    Shorts can't distort this !!

  • Human trials for Zika Virus ..40 healthy subjects...it now starts for us and ehds for the shorts..As Trump would say "by by "..Or buy buy..

    Sentiment: Strong Buy

  • Inovio Pharmaceuticals (NASDAQ:INO) and GeneOne Life Science say they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine to prevent infection from this concerning virus. This phase I, open-label, dose-ranging study with 40 healthy subjects will evaluate the safety, tolerability and immunogenicity of GLS-5700 administered intradermally with CELLECTRA, Inovio’s proprietary DNA delivery device.

    The stock decreased 2.51% or $0.27 on June 17, hitting $10.47. Inovio Pharmaceuticals Inc (NASDAQ:INO) has risen 47.26% since November 11, 2015 and is uptrending. It has outperformed by 47.44% the S&P500.

    Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer,

  • garysnoop1 by garysnoop1 Jun 19, 2016 3:01 PM Flag

    Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV

    Trial Stage:
    Phase II

    Status:
    This study is ongoing, but not recruiting participants

    Purpose:
    This research study of an investigational synthetic DNA vaccine is enrolling women with CIN 2/3 or CIN 3 associated with HPV type 16 or HPV type 18. The goal is to evaluate whether the cervical lesions will regress to CIN 1 or less within nine months after the first treatment in this study. A secondary goal will be to assess the clearance of HPV 16 and HPV 18.

    Study title:
    Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation with CELLECTRA®-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 with Documented HPV 16 or 18

    Study identifier:
    HPV-003 Clinical Research Study

    Treatment:
    VGX-3100

    For more information please go to the study protocol.

    Disease:
    Head and neck cancer caused by HPV

    Trial Stage:
    Phase I/IIa

    Status:
    This study is currently recruiting participants

    Purpose:
    This is a phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine (VGX-3100 and INO-9012) delivered by electroporation to subjects with HPV 16 and HPV 18 associated head and neck squamous cell cancer.

    Study title:
    Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma

    Study identifier:
    HPV-005 Clinical Research Study

    Treatment:
    INO-3112 (VGX-3100 and INO-9012)

    For more information please go to the study protocol.

    Disease:
    Cervical cancer caused by HPV

    Trial Stage:
    Phase I/IIa

    Status:
    This study is currently recruiting participants

    Purpose:
    This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine (VGX-3100 and INO-9012) delivered by electroporation to female subjects with HPV 16 or 18 positive cervical carcinoma.

    Study title:
    A Study of VGX-3100 and INO-9012 DNA Vaccine With Electroporation in Patients With Cervical Cancer

    Study identifier:
    HPV-004 Clinical Research Study

    Treatment:
    INO-3112 (VGX-3100 and INO-9012)

    For more information please go to the study protocol.

    Disease:
    Aerodigestive cancer caused by HPV

    Trial Stage:
    Phase I

    Status:
    This study is currently recruiting participants

    Purpose:
    This is a phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 delivered by electroporation to subjects with HPV-6 associated aerodigestive malignancies.

    Study title:
    Pilot Study of HPV Specific Immunotherapy in Subjects with HPV-6 Associated Aerodigestive Malignancies

    Study identifier:
    HPV-006 Clinical Research Study

    Treatment:
    INO-3106 + INO-9012

    For more information please go to the study protocol.

    Disease:
    Breast, lung, and pancreatic cancer

    Trial Stage:
    Phase I

    Status:
    This study is currently recruiting participants

    Purpose:
    This is a phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy. Subjects will be enrolled into one of six treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.

    Study title:
    A Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy

    Study identifier:
    NCT02327468

    Treatment:
    INO-1400

    Sentiment: Strong Buy

  • What are you thinking??..Soon you all will be on welfare with the kind of thinking I see comming from this co..@45k a year ...milk it for what it's worth I guess..

  • garysnoop1 garysnoop1 Jun 16, 2016 1:32 PM Flag

    You probably have six mo. till your short position will have you moving in with your next of kin.

    Sentiment: Strong Buy

  • garysnoop1 by garysnoop1 Jun 16, 2016 12:12 PM Flag

    good reading..

    Sentiment: Strong Buy

  • Reply to

    The case for Inovio..to own or not to own..

    by garysnoop1 Jun 16, 2016 11:12 AM
    garysnoop1 garysnoop1 Jun 16, 2016 11:20 AM Flag

    Which company will be the big winner in the fight against the Zika virus?. However, if I had to place a bet right now, my money would be on Inovio. So is mine..

CCCR
1.79-0.02(-1.11%)Jul 1 3:59 PMEDT